TGFB1 and neoplasm: Mechanisms related to the TGF‐β‐mediated bypass of ICI therapy, and the current view over strategies to rescue tumour immunity from the impact of this cytokine in order to improve the efficacy of anti‐PD‐(L)1 are described in this paper.